Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial

Marstacimab (PF-06741086) is under development for the treatment of hemophilia A and hemophilia B. It’s administered through intravenous or subcutaneous route. It is a monoclonal antibody that targets tissue factor pathway inhibitor (TFPI). The study demonstrates statistically significant and clinically relevant reduction in annualized bleeding rate compared to prophylaxis and on-demand intravenous regimens. Marstacimab, if approved, has the potential to become the first once-weekly subcutaneous treatment for people with hemophilia B and the first treatment administered as a flat dose for people with hemophilia A or B. Read more.

Source: Pfizer, April 2023